Literature DB >> 7999601

One-week therapy with oral terbinafine in cases of tinea cruris/corporis.

A Farag1, M Taha, S Halim.   

Abstract

The use of oral terbinafine in the treatment of superficial dermatophyte infections has been extensively studied, using different treatment regimens. To evaluate the efficacy of short-term therapy with oral terbinafine in cases of tinea cruris/corporis, 22 patients (21 male and one female) with mycologically proven tinea cruris/corporis, were included in the present study. Each patient received one tablet of terbinafine 250 mg daily for 1 week. Patients were followed-up for 6 weeks after completion of treatment. Clinical and mycological assessments were performed at the end of treatment, and at the end of the follow-up period. The mean sum of scores of signs and symptoms in all patients decreased significantly from 12.36 before treatment to 0 at the end of the follow-up period, and mycological investigations were negative in all patients at the end of the follow-up period. Our results show that 1-week therapy with oral terbinafine is highly effective in the treatment of tinea cruris/corporis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999601     DOI: 10.1111/j.1365-2133.1994.tb04983.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Current management of fungal infections.

Authors:  J F Meis; P E Verweij
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Correlation of In Vitro Susceptibility Based on MICs and Squalene Epoxidase Mutations with Clinical Response to Terbinafine in Patients with Tinea Corporis/Cruris.

Authors:  Ananta Khurana; Aradhana Masih; Anuradha Chowdhary; Kabir Sardana; Sagar Borker; Aastha Gupta; R K Gautam; P K Sharma; Dhruv Jain
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

3.  Microsporum fulvum, an ignored pathogenic dermatophyte: a new clinical isolation from Iran.

Authors:  Sadegh Nouripour-Sisakht; Ali Rezaei-Matehkolaei; Mahdi Abastabar; Mohammad Javad Najafzadeh; Kazuo Satoh; Bahram Ahmadi; Leila Hosseinpour
Journal:  Mycopathologia       Date:  2013-05-23       Impact factor: 2.574

4.  Update on terbinafine with a focus on dermatophytoses.

Authors:  Jason G Newland; Susan M Abdel-Rahman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-21

5.  Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis.

Authors:  P Ravindra Babu; A J S Pravin; Gaurav Deshmukh; Dhiraj Dhoot; Aniket Samant; Bhavesh Kotak
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

6.  Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD?

Authors:  Kabir Sardana; Aastha Gupta
Journal:  Indian J Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.494

7.  Relapse after Oral Terbinafine Therapy in Dermatophytosis: A Clinical and Mycological Study.

Authors:  Imran Majid; Gousia Sheikh; Farhath Kanth; Rubeena Hakak
Journal:  Indian J Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.